Physician profile
Kim Ng
NPI 1003803685
$1,818.88
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $53.11 · 2021: $63.88 · 2022: $488 · 2023: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.23 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $294.87 | 2019-2023 | Erleada |
| Incyte Corporation | $172.45 | 2019-2022 | |
| Exelixis INC. | $135.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $94.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $93.38 | 2023 | |
| Pfizer INC. | $83.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.93 | 2021-2023 | Opdualag |
| Seagen INC. | $76.91 | 2021-2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $70.65 | 2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $61.68 | 2022-2023 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $58.95 | 2022-2023 | Zejula |
| Gilead Sciences, INC. | $55.31 | 2022-2023 | Trodelvy |
| Puma Biotechnology, INC. | $54.29 | 2022-2023 | |
| Emmaus Medical, INC. | $49.69 | 2022-2023 | Endari |
| Astrazeneca Pharmaceuticals LP | $49.51 | 2023 | Imfinzi, Enhertu |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $49.47 | 2022-2023 | Iclusig |
| Adaptive Biotechnologies Corporation | $45.11 | 2022-2023 | Clonoseq |
| Celgene Corporation | $39.83 | 2022-2023 | Reblozyl |
| Foundation Medicine, INC. | $28.74 | 2023 | Foundationone Liquid Cdx |
| Karyopharm Therapeutics INC. | $22.76 | 2022 | |
| Taiho Oncology, INC. | $22.68 | 2022 | |
| Amgen INC. | $22.50 | 2022 | |
| Merck Sharp & Dohme LLC | $22.07 | 2023 | Lynparza, Keytruda |
| Morphosys, US INC. | $20.37 | 2022 | |
| Genentech USA, INC. | $19.12 | 2023 | Tecentriq |
| Novocure INC. | $19.12 | 2022 | |
| Eisai INC. | $18.62 | 2023 | |
| Genzyme Corporation | $17.13 | 2023 | |
| Mirati Therapeutics, INC. | $14.16 | 2023 | Krazati |
| Astellas Pharma US INC | $14.04 | 2023 | Xtandi |
| Daiichi Sankyo INC. | $13.38 | 2023 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.